A potentially important therapeutic outcome of the findings in our study is that tumours retaining an intact p53 pathway and, thereby, a proficient G1/S checkpoint are as sensitive to fraction size as dose-limiting normal tissues, undermining the clinical rationale for small fractions in such tumours. The gene discussed is TP53; the disease is neoplasm.